Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as of July 3, 2025:
Total number of shares outstanding:
92,183,523 ordinary shares
6,434 Preferred Shares 2016
7,581 Preferred Shares 2017
Total number of theoretical voting rights (1):
Total number of exercisable voting rights (2):
92,962,943
92,944,368
(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.
(2) The total number of exercisable voting rights (or "net" voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code Ticker code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including "anticipate," "believe," "can," "could," "estimate," "expect," "may," "might," "potential," "intend," "should," "will," or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250703076027/en/
Contacts
For additional information, please contact: Investors Innate Pharma Henry WheelerTel.: +33 (0)4 84 90 32 88Henry.wheeler@innate-pharma.fr
Media Relations NewCap Arthur RouilléTel.: +33 (0)1 44 71 00 15innate@newcap.eu
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
'This bull market in equities has a serious problem': Strategist warns a crucial AI-stock index is sending a potential bubble signal
The AI trade may be fueling a stock-market bubble, warns Sevens Report Research's Tom Essaye. Semiconductor stocks' performance is lagging, raising concerns about the AI-driven market rally. Plus, bubbles tend to form late-cycle, Essaye said, and the US economic outlook is weakening. It's one of the biggest mysteries in markets right now: Is the AI trade driving a stock-market bubble? While earnings remain impressively strong, the potential warning signs of a bubble are there. The S&P 500 is sitting near all-time highs after a 28% rally since early April and 57% gains since ChatGPT was announced in November 2022. Meme stocks are ripping, suggesting investor sentiment is abnormally elevated. Excitement around AI has also driven up market valuations to levels consistent with prior major bubbles, like those seen in 1929 and 2000. Tom Essaye, the founder of Sevens Report whose clients include advisors at some of Wall Street's biggest firms, recently addressed the topic in a couple of client notes. "Every bubble in modern market history has been based on a narrative, whether it be the internet or real estate. Critically, that given narrative is widely perceived by the investment world to be a source of unlimited earnings growth across most market sectors," he wrote in an August 1 note. "Today, that potentially bubble-inflating theme is unquestionably AI technology." As Essaye sees it, the best way to measure the health of the AI trade is to look at how semiconductor stocks overall are behaving, as chips are the lifeblood of AI technology. One can do this using the PHLX Semiconductor Index (SOX), a group of 30 stocks, he said. Comparing the index's performance to the S&P 500 over the last couple of years shows "this bull market in equities has a serious problem," he said. The concern for Essaye is that SOX still sits below its July 2024 highs while the S&P 500 has risen by almost 14% over that time. This suggests the market's rally, which is largely being fueled by the AI narrative, could be in an unhealthy place if many AI stocks themselves are failing to keep up their momentum. "The takeaway here is that if AI remains the primary source of bullish optimism for a continued rally in the broader stock market in the months and quarters ahead, this market is in trouble and at risk of rolling over sooner than later as the SOX should still be leading the market higher like it was in 2024, not lagging considerably over the last 12 months," he wrote. "That divergence in index performance is meaningful, and if we see the SOX roll over in the weeks or months ahead and start selling off materially, the S&P 500 will almost certainly not be far behind." Here's the performance of an ETF that tracks the SOX index over the last three years: And the S&P 500's performance: Another sign of a potential bubble, and perhaps of trouble ahead for stocks, is that the US economic outlook appears to be weakening, Essaye said. Bubbles usually form late in an economic cycle, Essaye said, and a recession usually causes them to burst. Job gains over the last few months have been poor, as payrolls data released on August 1 showed, raising recession fears. Plus, continuing jobless claims are creeping up, he said. Essaye wrote in an August 8 note that "it is critical to keep close tabs on economic data right now," adding that "stretched valuations in the wake of the S&P 500's rapid ~85% trough-to-peak rally since the October 2022 lows were established leaves the broader equity market vulnerable to considerable downside in the quarters ahead, pending economic resilience." Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
SoundHound's Post-Q2 Rally Explained: Should You Buy SOUN Stock Now?
Shares of SoundHound AI (SOUN) staged a sharp rebound after the company delivered a blowout second quarter, setting a new revenue record and lifting its full-year outlook. SOUN stock surged more than 27% in morning today after the results were announced, as investors cheered the company's accelerating momentum in the fast-growing conversational and voice AI market. The rally comes after a turbulent stretch for the stock. From a high of $24.98, SOUN endured a steep decline amid mounting concerns about its high valuations and broader economic headwinds. Selling pressure intensified in the months leading up to the Q2 release, leaving the stock deep in the red on a year-to-date basis. Despite the selloff, SoundHound's business fundamentals have remained strong, with demand for its AI technology continuing to expand across multiple industries. More News from Barchart Robinhood Stock Seemingly Can't Be Stopped in 2025. Is It Too Late to Buy HOOD Here? Dear Ford Stock Fans, Mark Your Calendar for August 11 Cathie Wood Is Buying Shares of This Little-Known Ethereum Treasury Company. Should You? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. The first quarter of 2025 had already hinted at the company's growth potential, with revenue climbing 151% year-over-year to $29.1 million. That performance had surpassed even the impressive 101% year-over-year growth registered in Q4 2024. But Q2 took things to another level. The company reported $42.7 million in revenue, a staggering 217% increase from last year's second quarter. This was driven by a growing addressable market, the addition of new customers, and successful cross-selling initiatives. Such explosive top-line growth reflects the surging demand for its voice AI solutions. As businesses in sectors ranging from automotive to hospitality seek to integrate conversational AI into their customer interactions, SoundHound's technology is gaining traction. This broadening adoption solidifies its leadership position in the space and sets the stage for sustained revenue expansion. SoundHound's Expansion Gains Speed SoundHound is firing on all cylinders, with growth momentum building quarter after quarter, with no signs of slowing down. The company has been making significant inroads across its key business segments, including automotive, AI-powered enterprise customer service, and AI-driven automation for restaurants. In the second quarter, it crossed a significant milestone, processing more than 1 billion queries per month on its platform, underscoring the scale and adoption of its technology. The rollout of its Agentic AI platform is emerging as the new growth catalyst for the company. This innovation has provided a tailwind across the business, bolstered by strategic channel investments that are beginning to pay off. Expanded enterprise partnerships and deeper engagement with existing partners have contributed meaningfully to results, positioning the company for continued expansion. In automotive, SoundHound signed a new original equipment manufacturer (OEM) in China, while enjoying a double-digit lift in average selling prices thanks to broader integration of its generative AI solutions. Its restaurant business is also performing exceptionally well, with location deployments accelerating quarter-over-quarter. The company now powers more than 14,000 restaurant locations with its Voice AI ordering technology, an increase of 1,000 locations in Q2 alone. Diversification has been another bright spot. During the first half of the year, no single customer accounted for more than 10% of total revenue, reducing concentration risk and creating a more stable growth foundation. Q2 also benefited from strong close rates on major deals, a trend that could sustain in future quarters. Thanks to the strong demand, SoundHound raised its 2025 revenue outlook to $160 million to $178 million from $157 million to $177 million. Recent acquisitions have strengthened both its capabilities and customer base, accelerating growth and creating new opportunities. While expansion has been rapid, SoundHound is keeping a close eye on costs. Management is pursuing operational efficiency through cloud integrations and workforce optimization, with generative AI playing a key role in enhancing productivity. With profitability in sight, the company remains confident in its path toward achieving adjusted EBITDA profitability by the end of 2025. The Bottom Line on SoundHound Stock SoundHound's Q2 results showcased explosive revenue growth, expanding market adoption, and a path toward profitability. With diversified revenue streams, strategic partnerships, and its agentic AI platform gaining traction, the company is positioned for sustained momentum. Analysts label SOUN stock a 'Moderate Buy.' Still, if SoundHound maintains this growth trajectory and edges closer to profitability, the current rally could be more than just a short-term rebound. On the date of publication, Amit Singh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Bournemouth to Sign €40M-Rated Lille Ace as Incoming PSG Star's Replacement
PSG and Bournemouth had been locked in a stalemate over Illia Zabarnyi, with neither side willing to budge. That's changed, as the French club is now on the verge of signing the Ukrainian defender. According to TalkSPORT, PSG have reached an agreement with Bournemouth to sign Zabarnyi for €63 million. After weeks of negotiations, both clubs appear satisfied with the fee to finalize the deal. Bournemouth have already lined up a replacement. On Friday, RMC Sport's Fabrice Hawkins reported that Bafodé Diakité has agreed to a five-year contract with the Premier League club. The sticking point had been Lille's €40 million asking price, but it appears an agreement has been reached there as well. Bouremouth find replacement for incoming PSG standoutOn Saturday, Foot Mercato's Santi Aouna reported that the clubs had reached an agreement on a €40 million transfer fee — the figure the Ligue 1 side had been seeking to part ways with the player. Bournemouth, PSG, and Zabarnyi are all likely content with what has transpired. The Ukraine standout gets his move to Paris, PSG get a young and talented center-back while the Premier League club get a significant fee and a replacement. Transfer expert Fabrizio Romano previously reported that Zabarnyi was keen to join PSG and even reached a verbal agreement with them back in June. Despite some rumors, Romano made it clear there haven't been any serious talks with Tottenham Hotspur as Premier League clubs are set to miss out. Well, Zabarnyi is about to be joining the European champions.
